{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T20:36:24Z","timestamp":1770237384507,"version":"3.49.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s13555-025-01573-1","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T06:27:26Z","timestamp":1763792846000},"page":"499-520","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Is Cumulative Life Course Impairment Considered in Psoriasis Management? A Multinational Survey of People with Psoriasis and Healthcare Professionals"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3449-4451","authenticated-orcid":false,"given":"Raymond","family":"Matthews","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0064-8707","authenticated-orcid":false,"given":"April W.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4026-8728","authenticated-orcid":false,"given":"Matthias","family":"Augustin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0144-2927","authenticated-orcid":false,"given":"Christopher","family":"Baker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4266-0771","authenticated-orcid":false,"given":"Jos\u00e9 Manuel","family":"Carrascosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7596-892X","authenticated-orcid":false,"given":"Brian","family":"Kirby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4730-2164","authenticated-orcid":false,"given":"Richard","family":"Langley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8449-1809","authenticated-orcid":false,"given":"Sandy","family":"McBride","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5573-1754","authenticated-orcid":false,"given":"Adam","family":"Reich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0165-3831","authenticated-orcid":false,"given":"Ricardo","family":"Romiti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7624-3290","authenticated-orcid":false,"given":"Francesca","family":"Sampogna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2918-6481","authenticated-orcid":false,"given":"Richard B.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,22]]},"reference":[{"issue":"4","key":"1573_CR1","doi-asserted-by":"publisher","first-page":"210","DOI":"10.2310\/7750.2011.10066","volume":"15","author":"K Papp","year":"2011","unstructured":"Papp K, Gulliver W, Lynde C, Poulin Y, Ashkenas J, Canadian Psoriasis Guidelines Committee. Canadian guidelines for the management of plaque psoriasis: overview. J Cutan Med Surg. 2011;15(4):210\u20139.","journal-title":"J Cutan Med Surg"},{"issue":"2","key":"1573_CR2","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jaad.2016.10.017","volume":"76","author":"AW Armstrong","year":"2017","unstructured":"Armstrong AW, Siegel MP, Bagel J, et al. From the medical board of the National Psoriasis Foundation: treatment targets for plaque psoriasis. J Am Acad Dermatol. 2017;76(2):290\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1573_CR3","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/jdv.15340","volume":"33","author":"F Amatore","year":"2019","unstructured":"Amatore F, Villani AP, Tauber M, Viguier M, Guillot B. French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults. J Eur Acad Dermatol Venereol. 2019;33(3):464\u201383.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1573_CR4","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/bjd.19039","volume":"183","author":"CH Smith","year":"2020","unstructured":"Smith CH, Yiu ZZN, Bale T, et al. British Association of Dermatologists\u2019 Clinical Standards Unit. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. Br J Dermatol. 2020;183(4):628\u201337.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1573_CR5","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/1346-8138.15196","volume":"47","author":"H Saeki","year":"2020","unstructured":"Saeki H, Terui T, Morita A, et al. Japanese guidance for use of biologics for psoriasis (the 2019 version). J Dermatol. 2020;47(3):201\u201322.","journal-title":"J Dermatol"},{"key":"1573_CR6","unstructured":"Argentine Society of Psoriasis. Argentine guidelines for the systemic treatment of moderate to severe psoriasis in adult patients. http:\/\/www.soarpso.org\/recursos\/archivos\/AG_psoriasis_2020_english.pdf. Accessed July 2025."},{"issue":"11","key":"1573_CR7","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1111\/jdv.16915","volume":"34","author":"A Nast","year":"2020","unstructured":"Nast A, Smith C, Spuls PI, et al. Euroguiderm guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34(11):2461\u201398.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1573_CR8","unstructured":"Gomez M, Amaya M, Garc\u00eda Hidalgo L, et al. https:\/\/071d2186-dd73-483c-9a765f7e2b5bca70.filesusr.com\/ugd\/f187f1_651eb668a34b494f9a4be43a8b8773cc.pdf. Accessed July 2025."},{"key":"1573_CR9","doi-asserted-by":"crossref","unstructured":"Carrascosa JM, Puig L, Belinch\u00f3n Romero I, et al. Practical update of the Recommendations Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPS) on the Treatment of Psoriasis with Biologic Therapy. Part 1. Concepts and General Management of Psoriasis with Biologic Therapy. Actas Dermosifiliogr. 2022;113(3):261\u201377.","DOI":"10.1016\/j.ad.2021.10.011"},{"issue":"4","key":"1573_CR10","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/ajd.14138","volume":"64","author":"P Foley","year":"2023","unstructured":"Foley P, Gebauer K, Sullivan J, et al. Australian consensus: treatment goals for moderate to severe psoriasis in the era of targeted therapies - adult patients. Australas J Dermatol. 2023;64(4):476\u201387.","journal-title":"Australas J Dermatol"},{"issue":"3","key":"1573_CR11","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1159\/000113150","volume":"216","author":"DA Revicki","year":"2008","unstructured":"Revicki DA, Willian MK, Menter A, Saurat JH, Harnam N, Kaul M. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. Dermatology. 2008;216(3):260\u201370.","journal-title":"Dermatology"},{"issue":"1","key":"1573_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00403-010-1080-1","volume":"303","author":"U Mrowietz","year":"2011","unstructured":"Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1\u201310.","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"1573_CR13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jaad.2016.03.026","volume":"75","author":"B Strober","year":"2016","unstructured":"Strober B, Papp KA, Lebwohl M, et al. Clinical meaningfulness of complete skin clearance in psoriasis. J Am Acad Dermatol. 2016;75(1):77-82.e7.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1573_CR14","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.jaad.2014.05.001","volume":"71","author":"J Takeshita","year":"2014","unstructured":"Takeshita J, Callis Duffin K, Shin DB, et al. Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting. J Am Acad Dermatol. 2014;71(4):633\u201341.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1573_CR15","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3109\/09546634.2015.1093589","volume":"27","author":"SR Feldman","year":"2016","unstructured":"Feldman SR, Bushnell DM, Klekotka PA, et al. Differences in psoriasis signs and symptom severity between patients with clear and almost clear skin in clinical practice. J Dermatolog Treat. 2016;27(3):224\u20137.","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"1573_CR16","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/jdv.14007","volume":"31","author":"L Puig","year":"2017","unstructured":"Puig L, Thom H, Mollon P, Tian H, Ramakrishna GS. Clear or almost clear skin improves the quality of life in patients with moderate-to-severe psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2017;31(2):213\u201320.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1573_CR17","unstructured":"Reed C, Hill J, Schuster C, Hetherington J, Lucas J, Piaserico S. The benefit of complete versus almost complete skin clearance from the patient perspective: an assessment of real-world patients with psoriasis in five European countries. 29th European Academy of Dermatology and Venereology (EADV); Virtual, 2020: P1333."},{"issue":"3","key":"1573_CR18","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3109\/09546634.2014.943687","volume":"26","author":"HN Viswanathan","year":"2015","unstructured":"Viswanathan HN, Chau D, Milmont CE, et al. Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis. J Dermatolog Treat. 2015;26(3):235\u20139.","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"1573_CR19","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1016\/j.jaad.2020.08.039","volume":"84","author":"JJ Wu","year":"2021","unstructured":"Wu JJ, Schrader A, McLean RR, Valdecantos W, Etzel C, Singh R. Improvement in body surface area is associated with better quality of life among patients with psoriasis in the Corrona Psoriasis Registry. J Am Acad Dermatol. 2021;84(6):1715\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1573_CR20","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1080\/09546634.2020.1772454","volume":"33","author":"NJ Korman","year":"2022","unstructured":"Korman NJ, Malatestinic W, Goldblum OM, et al. Assessment of the benefit of achieving complete versus almost complete skin clearance in psoriasis: a patient\u2019s perspective. J Dermatolog Treat. 2022;33(2):733\u20139.","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"1573_CR21","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/bjd.17259","volume":"180","author":"F Sampogna","year":"2019","unstructured":"Sampogna F, Puig L, Spuls P, et al. Reversibility of alexithymia with effective treatment of moderate-to-severe psoriasis: longitudinal data from EPIDEPSO. Br J Dermatol. 2019;180(2):397\u2013403.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1573_CR22","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1159\/000479163","volume":"86","author":"CEM Griffiths","year":"2017","unstructured":"Griffiths CEM, Fava M, Miller AH, et al. Impact of ixekizumab treatment on depressive symptoms and systemic inflammation in patients with moderate-to-severe psoriasis: an integrated analysis of three phase\u00a03 clinical studies. Psychother Psychosom. 2017;86(5):260\u20137.","journal-title":"Psychother Psychosom"},{"issue":"11","key":"1573_CR23","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1111\/jdv.15012","volume":"32","author":"KB Gordon","year":"2018","unstructured":"Gordon KB, Armstrong AW, Han C, et al. Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the phase\u00a03 VOYAGE 2 study. J Eur Acad Dermatol Venereol. 2018;32(11):1940\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1573_CR24","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jaad.2017.08.051","volume":"78","author":"B Strober","year":"2018","unstructured":"Strober B, Gooderham M, de Jong EMGJ, et al. Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Am Acad Dermatol. 2018;78(1):70\u201380.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"1573_CR25","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1001\/jamadermatol.2020.3617","volume":"156","author":"M Augustin","year":"2020","unstructured":"Augustin M, Lambert J, Zema C, et al. Effect of risankizumab on patient-reported outcomes in moderate to severe psoriasis: the UltIMMa-1 and UltIMMa-2 randomized clinical trials. JAMA Dermatol. 2020;156(12):1344\u201353.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"1573_CR26","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3712","volume":"101","author":"M Talamonti","year":"2021","unstructured":"Talamonti M, Malara G, Natalini Y, et al. Secukinumab improves patient perception of anxiety and depression in patients with moderate to severe psoriasis: a post hoc analysis of the SUPREME study. Acta Derm Venereol. 2021;101(3):adv00422.","journal-title":"Acta Derm Venereol"},{"issue":"9","key":"1573_CR27","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1111\/j.1468-3083.2010.03705.x","volume":"24","author":"AB Kimball","year":"2010","unstructured":"Kimball AB, Gieler U, Linder D, Sampogna F, Warren RB, Augustin M. Psoriasis: is the impairment to a patient\u2019s life cumulative? J Eur Acad Dermatol Venereol. 2010;24(9):989\u20131004.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1573_CR28","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ad.2013.02.009","volume":"105","author":"S Ros","year":"2014","unstructured":"Ros S, Puig L, Carrascosa JM. Cumulative life course impairment: the imprint of psoriasis on the patient\u2019s life. Actas Dermosifiliogr. 2014;105(2):128\u201334.","journal-title":"Actas Dermosifiliogr"},{"issue":"217","key":"1573_CR29","first-page":"102","volume":"96","author":"MD Linder","year":"2016","unstructured":"Linder MD, Piaserico S, Augustin M, et al. Psoriasis - The Life Course Approach. Acta Derm Venereol. 2016;96(217):102\u20138.","journal-title":"Acta Derm Venereol"},{"issue":"Suppl 1","key":"1573_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2133.2011.10280.x","volume":"164","author":"RB Warren","year":"2011","unstructured":"Warren RB, Kleyn CE, Gulliver WP. Cumulative life course impairment in psoriasis: patient perception of disease-related impairment throughout the life course. Br J Dermatol. 2011;164(Suppl 1):1\u201314.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1573_CR31","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.abd.2023.08.006","volume":"99","author":"R Romiti","year":"2024","unstructured":"Romiti R, Magalh\u00e3es RF, Duarte GV. Cumulative life course impairment in patients with dermatological diseases, with a focus on psoriasis. An Bras Dermatol. 2024;99(2):269\u201376.","journal-title":"An Bras Dermatol"},{"issue":"11","key":"1573_CR32","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1111\/jdv.17348","volume":"35","author":"CC von St\u00fclpnagel","year":"2021","unstructured":"von St\u00fclpnagel CC, Augustin M, D\u00fcpmann L, da Silva N, Sommer R. Mapping risk factors for cumulative life course impairment in patients with chronic skin diseases - a systematic review. J Eur Acad Dermatol Venereol. 2021;35(11):2166\u201384.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1573_CR33","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/j.1365-2133.2009.09593.x","volume":"162","author":"M Augustin","year":"2010","unstructured":"Augustin M, Glaeske G, Radtke MA, Christophers E, Reich K, Sch\u00e4fer I. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol. 2010;162(3):633\u20136.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1573_CR34","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1159\/000455840","volume":"232","author":"P Jensen","year":"2016","unstructured":"Jensen P, Skov L. Psoriasis and obesity. Dermatology. 2016;232(6):633\u20139.","journal-title":"Dermatology"},{"key":"1573_CR35","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/1477-7525-11-78","volume":"11","author":"ZU Bhatti","year":"2013","unstructured":"Bhatti ZU, Salek SS, Bolton CE, et al. The development and validation of the major life changing decision profile (MLCDP). Health Qual Life Outcomes. 2013;11:78.","journal-title":"Health Qual Life Outcomes"},{"issue":"12","key":"1573_CR36","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1093\/ced\/llae282","volume":"49","author":"LMH Arancio","year":"2024","unstructured":"Arancio LMH, D\u2019Amico D, Dastoli S, et al. Early intervention and cumulative life course impairment in psoriasis: a review. Clin Exp Dermatol. 2024;49(12):1525\u201331.","journal-title":"Clin Exp Dermatol"},{"issue":"12","key":"1573_CR37","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1111\/jdv.15065","volume":"32","author":"A Armstrong","year":"2018","unstructured":"Armstrong A, Jarvis S, Boehncke WH, et al. Patient perceptions of clear\/almost clear skin in moderate-to-severe plaque psoriasis: results of the Clear About Psoriasis worldwide survey. J Eur Acad Dermatol Venereol. 2018;32(12):2200\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1573_CR38","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/jdv.14684","volume":"32","author":"JMPA van den Reek","year":"2018","unstructured":"van den Reek JMPA, Seyger MMB, van L\u00fcmig PPM, et al. The journey of adult psoriasis patients towards biologics: past and present - results from the BioCAPTURE registry. J Eur Acad Dermatol Venereol. 2018;32(4):615\u201323.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1573_CR39","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","volume":"156","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Puig L, Joshi A, et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156(3):258\u201369.","journal-title":"JAMA Dermatol"},{"issue":"9","key":"1573_CR40","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.120.011199","volume":"13","author":"H Choi","year":"2020","unstructured":"Choi H, Uceda DE, Dey AK, et al. Treatment of psoriasis with biologic therapy is associated with improvement of coronary artery plaque lipid-rich necrotic core: results from a prospective, observational study. Circ Cardiovasc Imaging. 2020;13(9):e011199.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"1","key":"1573_CR41","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaad.2020.08.032","volume":"84","author":"RG Langley","year":"2021","unstructured":"Langley RG, Poulin Y, Srivastava B, et al. Reduced risk of mortality associated with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR): a nested case-control analysis. J Am Acad Dermatol. 2021;84(1):60\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1573_CR42","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jid.2018.07.029","volume":"139","author":"A Egeberg","year":"2019","unstructured":"Egeberg A, Thyssen JP, Burisch J, Colombel JF. Incidence and risk of inflammatory bowel disease in patients with psoriasis\u2014a nationwide 20-year cohort study. J Invest Dermatol. 2019;139(2):316\u201323.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"1573_CR43","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1136\/annrheumdis-2021-219961","volume":"81","author":"P Gisondi","year":"2022","unstructured":"Gisondi P, Bellinato F, Targher G, Idolazzi L, Girolomoni G. Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. Ann Rheum Dis. 2022;81(1):68\u201373.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1573_CR44","doi-asserted-by":"publisher","first-page":"e200","DOI":"10.1016\/S2665-9913(23)00034-6","volume":"5","author":"S Singla","year":"2023","unstructured":"Singla S, Putman M, Liew J, Gordon K. Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study. Lancet Rheumatol. 2023;5(4):e200\u20137.","journal-title":"Lancet Rheumatol"},{"key":"1573_CR45","unstructured":"European Pharmaceutical Market Research Association (EPhMRA). 2024 Code of Conduct. https:\/\/www.ephmra.org\/code-conduct-aer. Accessed 14 July 2025."},{"key":"1573_CR46","unstructured":"World Health Organization (WHO). Global report on psoriasis. 2016. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/204417\/9789241565189_eng.pdf.psoriasis?sequence=1#:~:text=The%20reported%20prevalence%20of%20psoriasis,100%20million%20individuals%20affected%20worldwide. Accessed 14 July 2025."},{"key":"1573_CR47","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18977","author":"CC Braren-von St\u00fclpnagel","year":"2023","unstructured":"Braren-von St\u00fclpnagel CC, Augustin M, Westphal L, Sommer R. Development of measurement tools to assess cumulative life course impairment in patients with chronic skin diseases. J Eur Acad Dermatol Venereol. 2023. https:\/\/doi.org\/10.1111\/jdv.18977.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1573_CR48","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1590","volume":"369","author":"R Parisi","year":"2020","unstructured":"Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590.","journal-title":"BMJ"},{"issue":"4","key":"1573_CR49","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s13555-022-00695-0","volume":"12","author":"A Armstrong","year":"2022","unstructured":"Armstrong A, Bohannan B, Mburu S, et al. Impact of psoriatic disease on quality of life: interim results of a global survey. Dermatol Ther (Heidelb). 2022;12(4):1055\u201364.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1573_CR50","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/jdv.12106","volume":"28","author":"P Mattei","year":"2014","unstructured":"Mattei P, Corey K, Kimball A. Psoriasis area severity index (PASI) and the dermatology life quality index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol. 2014;28:333\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1573_CR51","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1023\/B:QURE.0000018486.91360.00","volume":"13","author":"SM Skevington","year":"2004","unstructured":"Skevington SM, Lotfy M, O\u2019Connell KA. The World Health Organization\u2019s WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL group. Qual Life Res. 2004;13(2):299\u2013310.","journal-title":"Qual Life Res"},{"issue":"5","key":"1573_CR52","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/j.1365-2133.1997.tb01113.x","volume":"137","author":"DG Fortune","year":"1997","unstructured":"Fortune DG, Main CJ, O\u2019Sullivan TM, Griffiths CE. Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. Br J Dermatol. 1997;137(5):755\u201360.","journal-title":"Br J Dermatol"},{"issue":"10","key":"1573_CR53","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1111\/jdv.13150","volume":"29","author":"PC van de Kerkhof","year":"2015","unstructured":"van de Kerkhof PC, Reich K, Kavanaugh A, et al. Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey. J Eur Acad Dermatol Venereol. 2015;29(10):2002\u201310.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"1573_CR54","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1038\/jid.2009.112","volume":"129","author":"JM Gelfand","year":"2009","unstructured":"Gelfand JM, Dommasch ED, Shin DB, et al. The risk of stroke in patients with psoriasis. J Invest Dermatol. 2009;129(10):2411\u20138.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"1573_CR55","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1111\/j.1365-2133.2010.09941.x","volume":"163","author":"K Abuabara","year":"2010","unstructured":"Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol. 2010;163(3):586\u201392.","journal-title":"Br J Dermatol"},{"issue":"8","key":"1573_CR56","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1093\/eurheartj\/ehp567","volume":"31","author":"NN Mehta","year":"2010","unstructured":"Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010;31(8):1000\u20136.","journal-title":"Eur Heart J"},{"issue":"7","key":"1573_CR57","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1093\/rheumatology\/ket363","volume":"53","author":"R Queiro","year":"2014","unstructured":"Queiro R, Tej\u00f3n P, Alonso S, Coto P. Age at disease onset: a key factor for understanding psoriatic disease. Rheumatology (Oxford). 2014;53(7):1178\u201385.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"1573_CR58","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2287401","volume":"35","author":"B Strober","year":"2024","unstructured":"Strober B, Duffin KC, Lebwohl M, et al. Impact of psoriasis disease severity and special area involvement on patient-reported outcomes in the real world: an analysis from the CorEvitas psoriasis registry. J Dermatolog Treat. 2024;35(1):2287401.","journal-title":"J Dermatolog Treat"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01573-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01573-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01573-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T08:03:34Z","timestamp":1770192214000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01573-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,22]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1573"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01573-1","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,22]]},"assertion":[{"value":"30 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Raymond Matthews has received contracts or grants from National Institute for Health and Care Research UK, and support for attending meetings and\/or travel from UCB and Sanofi. April W Armstrong has received contracts or grants from AbbVie, ASLAN, Bristol Myers Squibb, Dermavant Sciences, Dermira, Eli Lilly, Galderma, Incyte, Janssen, Leo Pharma, Meiji Seika Pharma Co., Ltd, Modernizing Medicine, Nimbus Therapeutics, Novartis, Ortho Dermatologics, Pfizer, Sanofi Genzyme, UCB and Ventyx Biosciences. She has worked as a consultant at AbbVie, ASLAN, Almirall, Amgen, Arcutis Biotherapeutics, Beiersdorf, Bristol Myers Squibb, Dermavant, EPI Health, Eli Lilly, Janssen, LEO Pharma, Mindera, Nimbus, Organon & Co, Sanofi, Sun Pharmaceutical Industries, Takeda and Ventyx Biosciences. April W Armstrong has received payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from AbbVie, Amgen, Bristol Myers Squibb, Galderma, Janssen, Mindera, Organon & Co, Sanofi and Takeda. Lastly, she has been part of a Data Safety Monitoring Board or Advisory Board for Incyte, Regeneron, UCB, Boehringer Ingelheim and Parexel. Matthias Augustin has served as a consultant, lecturer, researcher, and\/or has received research grants from companies manufacturing drugs for chronic skin diseases, including AbbVie, Acelyrin, Almirall, Alumnis, Amgen, Aslan, Bayer, Beiersdorf, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celldex Therapeutics, Celltrion, Centocor, Coldplasmatech, CSL Behring, Curea, Dermavant, Dermira, Eli Lilly, Galderma, Genzyme, GlaxoSmithKline, Hexal, Incyte, Innovaderm, Janssen, Klinge, Leo Pharma, L\u2019Or\u00e9al, MC2, Medac, Meiji, Menlo, Merck, MoonLake Immunotherapeutics, MSD, Novartis, Pfizer, Regeneron, Sandoz, Sanofi, Skinuvita, Stallergenes Greer, Sun Pharmaceutical Industries, Takeda, Trevi, UCB and Viatris. Christopher Baker has worked as a consultant for AbbVie, Amgen, Bristol Myers Squibb, Janssen, Leo Pharma, Novartis and UCB Pharma. He has received payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from AbbVie, Amgen, Bristol Myers Squibb, Janssen, Leo Pharma, Novartis and UCB Pharma. Adam Reich has worked as a consultant or speaker for AbbVie, Bausch Health, Bioderma, Celgene, Chema Elektromet, Eli Lilly, Galderma, Janssen, Leo Pharma, Medac, Menlo Therapeutics, Novartis, Pierre-Fabre, Sandoz, Sanofi and Trevi, and participated as principal investigator or sub-investigator in clinical trials sponsored by AbbVie, AnaptysBio, Argenx, CellTrion, Drug Delivery Solutions Ltd, Galderma, Genentech, InflaRx, Janssen, Kymab Limited, Leo Pharma, Menlo Therapeutics, MetrioPharm, MSD, Novartis, Pfizer, Sanofi, Trevi, UCB and VielaBio. Adam Reich is an Editorial Board Member for\n                      Dermatology and Therapy\n                      . Adam Reich was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Jos\u00e9 Manuel Carrascosa has worked as a consultant for AbbVie, Novartis, Leo Pharma, Almirall, Johnson & Johnson, UCB, Bristol Myers Squibb, Pfizer, Sanofi, Lilly and Galderma. He has received payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from AbbVie, Novartis, Leo Pharma, Almirall, Johnson & Johnson, UCB, Bristol Myers Squibb, Pfizer, Sanofi, Lilly and Galderma. Jos\u00e9 Manuel Carrascosa has provided expert testimonials for AbbVie, Novartis, Leo Pharma, Almirall, Johnson and Johnson, UCB, Bristol Myers Squibb, Pfizer, Sanofi, Lilly and Galderma. He has received support for attending meetings and\/or travel from Johnson & Johnson, Lilly and Almirall. Lastly, Jos\u00e9 Manuel Carrascosa has been part of a Data Safety Monitoring Board or Advisory Board for AbbVie, Novartis, Leo Pharma, Almirall, Johnson & Johnson, UCB, Bristol Myers Squibb, Pfizer, Sanofi, Lilly and Galderma. Jose-Manuel Carrascosa is an Editorial Board Member for\n                      Dermatology and Therapy\n                      . Jose-Manuel Carrascosa was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Brian Kirby has received grants or contracts from AbbVie, Almirall, Novartis, MoonLake Therapeutics, AstraZeneca, Janssen, Leo Pharma, Novartis, Pfizer, Sandoz, Union and UCB. He has worked as a consultant for AbbVie, Almirall, Novartis, MoonLake Therapeutics, UCB, AstraZeneca, Janssen, Leo Pharma, Novartis, Pfizer, Sandoz and Union. Brian Kirby has received payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from AbbVie, Almirall, Novartis, MoonLake Therapeutics, UCB, AstraZeneca, Janssen, Leo Pharma, Novartis, Pfizer, Sandoz and Union. In addition, he has received support for attending meetings and\/or travel from AbbVie, Almirall, Novartis, MoonLake Therapeutics, UCB, AstraZeneca, Janssen, Leo Pharma, Novartis, Pfizer, Sandoz and Union. Brian Kirby has been part of a Data Safety Monitoring Board or Advisory Board for Arctic Bioscience and is a member of the BADBIR Steering Committee and the Clinical Advisory Group at RCPI. Richard Langley has grants or contracts from AbbVie, Janssen, Amgen, Leo Pharma, UCB, Union, Lilly, Novartis and Boehringer Ingelheim. He has worked as a consultant for AbbVie, Janssen, Amgen, Leo Pharma, UCB, Union, Lilly, Novartis and Boehringer Ingelheim. In addition, Richard Langley has received payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from AbbVie, Janssen, Amgen, Leo Pharma, UCB, Union, Lilly, Novartis and Boehringer Ingelheim. He has been part of a Data Safety Monitoring Board or Advisory Board for AbbVie, Janssen, Amgen, Leo Pharma, UCB, Union, Lilly, Novartis and Boehringer Ingelheim. Lastly, Richard Langley is Chair at Dalhousie UIRMF Investments Endowment and Chair at the Canadian Dermatology Association. Sandy McBride has worked as a consultant for AbbVie, Almirall, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen Cilag, Novartis, Pfizer and UCB. She has received payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from AbbVie, Almirall, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen Cilag, Novartis, Pfizer and UCB. Sandy McBride has received support for attending conferences from AbbVie, Johnson & Johnson, Eli Lilly and UCB. Ricardo Romiti has worked as a consultant for AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Galderma, Johnson & Johnson, Eli Lilly, Leo Pharma, Novartis, Pfizer, Sanofi, Sun Pharma Industries and UCB. He has received payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Galderma, Johnson & Johnson, Eli Lilly, Leo Pharma, Novartis, Pfizer, Sanofi, Sun Pharmaceutical Industries and UCB. Ricardo Romiti has received support for attending meetings and\/or travel from AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Johnson & Johnson and UCB. In addition, he has been part of a Data Safety Monitoring Board or Advisory Board for AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Johnson & Johnson, Eli Lilly, Leo Pharma, Novartis, Sun Pharma Industries and UCB. Lastly, Ricardo Romiti is an International League of Dermatological Societies (ILDS) Regional Director. Francesca Sampogna has been a consultant for AbbVie. Richard B Warren has received grants or contracts from AbbVie, Almirall, Amgen, Celgene, Janssen, Leo Pharma, Lilly, Novartis, Pfizer and UCB. He has worked as a consultant for AbbVie, Almirall, Amgen, Arena, Astellas, Avillion Life Sciences, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, DICE Therapeutics, Eli Lilly, Galderma, GSK, Janssen, Leo Pharma, Lilly, Meiji Pharma, Novartis, Pfizer, RAPT Therapeutics, Sanofi, Sun Pharma Industries, UCB and UNION. Richard B Warren has received payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from AbbVie, Almirall, Janssen, Lilly, Bristol Myers Squibb, Galderma and Novartis. Richard B Warren is an Editor-in-Chief for\n                      Dermatology and Therapy\n                      . Richard B Warren was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was conducted in accordance with the ethical principles of the Declaration of Helsinki (1964 and its later amendments). This survey-based study, which involved the collection of anonymised data and voluntary participation, was reviewed by Sermo, London UK (healthcare insights agency), who determined that formal ethical approval was not required for this type of market research [\n                      \n                      ].","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}